In the past week, FDMT stock has gone down by -3.14%, with a monthly decline of -7.39% and a quarterly plunge of -43.96%. The volatility ratio for the week is 6.27%, and the volatility levels for the last 30 days are 5.38% for 4D Molecular Therapeutics Inc The simple moving average for the past 20 days is -2.42% for FDMT’s stock, with a -60.81% simple moving average for the past 200 days.
Is It Worth Investing in 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Right Now?
The 36-month beta value for FDMT is also noteworthy at 2.75. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FDMT is 43.64M, and at present, short sellers hold a 18.75% of that float. The average trading volume of FDMT on November 15, 2024 was 782.06K shares.
FDMT) stock’s latest price update
4D Molecular Therapeutics Inc (NASDAQ: FDMT) has seen a rise in its stock price by 4.02 in relation to its previous close of 7.71. However, the company has experienced a -3.14% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-13 that 4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.24 per share a year ago.
Analysts’ Opinion of FDMT
Barclays, on the other hand, stated in their research note that they expect to see FDMT reach a price target of $459. The rating they have provided for FDMT stocks is “Overweight” according to the report published on April 15th, 2024.
Barclays gave a rating of “Overweight” to FDMT, setting the target price at $45 in the report published on April 15th of the current year.
FDMT Trading at -23.10% from the 50-Day Moving Average
After a stumble in the market that brought FDMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.88% of loss for the given period.
Volatility was left at 5.38%, however, over the last 30 days, the volatility rate increased by 6.27%, as shares sank -5.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.29% lower at present.
During the last 5 trading sessions, FDMT fell by -3.14%, which changed the moving average for the period of 200-days by -53.51% in comparison to the 20-day moving average, which settled at $8.22. In addition, 4D Molecular Therapeutics Inc saw -60.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FDMT starting from Bizily Scott, who sale 500 shares at the price of $16.33 back on Sep 16 ’24. After this action, Bizily Scott now owns 6,781 shares of 4D Molecular Therapeutics Inc, valued at $8,165 using the latest closing price.
Bizily Scott, the Chief Legal Officer of 4D Molecular Therapeutics Inc, sale 500 shares at $15.00 during a trade that took place back on Aug 19 ’24, which means that Bizily Scott is holding 6,781 shares at $7,500 based on the most recent closing price.
Stock Fundamentals for FDMT
Current profitability levels for the company are sitting at:
- -12026.86 for the present operating margin
- -531.43 for the gross margin
The net margin for 4D Molecular Therapeutics Inc stands at -10248.57. The total capital return value is set at -0.29. Equity return is now at value -33.00, with -29.90 for asset returns.
Based on 4D Molecular Therapeutics Inc (FDMT), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -4.57. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -119.25.
Currently, EBITDA for the company is -107.12 million with net debt to EBITDA at 0.99. When we switch over and look at the enterprise to sales, we see a ratio of 18149.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.33.
Conclusion
In summary, 4D Molecular Therapeutics Inc (FDMT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
